Dyno Therapeutics has formed a new research partnership with Roche, focusing on the development of next-generation ...

Privately held Dyno Therapeutics Inc. has added another notch to its adeno-associated virus (AAV) vectors development ...

Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering ...

Our heart muscle is studded with tiny dyads, intricately designed structures that manage incoming electrical signals and ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

Conformational changes on the capsid may be the cause of the charge differences between empty and full AAV capsids.

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...

Product launches is the main strategy followed by the manufacturers for insect cell lines market. On March 2020, Lonza has ...

George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...

Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...

Pharma presented positive preliminary data from eleven participants dosed in the CANaspire Phase 1/2 clinical trial of ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on BBIO stock, giving a Buy rating today. Salim Syed’s rating ...